-transparent.png){kind=logo}
The ADP-ribosyl moiety of NAD+ is consumed in reactions catalyzed by three classes of enzymes: poly(ADP-ribose) polymerase, protein mono(ADP-ribosyl)transferases, and NAD+ glycohydrolases. In this study, we have evaluated the selectivity of compounds originally identified as inhibitors of poly(ADP-ribose) polymerase on members of the three classes of enzymes. The 50% inhibitory concentration (IC50) of more than 20 compounds was determined in vitro for both poly(ADP-ribose) polymerase and mono(ADP-ribosyl)transferase A in an assay containing 300 microM NAD+. Of the compounds tested, benzamide was the most potent inhibitor of poly(ADP-ribose) polymerase with an IC50 of 3.3 microM. The IC50 for benzamide for mono(ADP-ribosyl)transferase A was 4.1 mM, and similar values were observed for four additional cellular mono(ADP-ribosyl)transferases. The IC50 for NAD+ glycohydrolase for benzamide was approximately 40 mM. For seven of the best inhibitors, inhibition of poly(ADP-ribose) polymerase in intact C3H1OT1/2 cells was studied as a function of the inhibitor concentration of the culture medium, and the concentration for 50% inhibition (culture medium IC50) was determined. Culture medium IC50 values for benzamide and its derivatives were very similar to in vitro IC50 values. For other inhibitors, such as nicotinamide, 5-methyl-nicotinamide, and 5-bromodeoxyuridine, culture medium IC50 values were 3-5-fold higher than in vitro IC50 values. These results suggest that micromolar levels of the benzamides in the culture medium should allow selective inhibition of poly(ADP-ribose) metabolism in intact cells. Furthermore, comparative quantitative inhibition studies should prove useful for assigning the biological effects of these inhibitors as an effect on either poly(ADP-ribose) or mono(ADP-ribose) metabolism.
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
January 1983,
Neurobehavioral toxicology and teratology,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
September 1994,
Molecular and cellular biochemistry,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
January 1980,
Advances in enzyme regulation,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
September 2019,
Biochemical pharmacology,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
January 1995,
Methods in enzymology,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
April 2021,
Nucleic acids research,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
January 2017,
Methods in molecular biology (Clifton, N.J.),
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
September 2016,
The FEBS journal,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
December 1985,
Biochemistry,
P W Rankin, and
E L Jacobson, and
R C Benjamin, and
J Moss, and
M K Jacobson
January 1997,
Advances in experimental medicine and biology,
